Drug Trial Radar · NCT06825624
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Oct 3, 2024
Primary completion
Oct 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and efficacy of HS-20093 in combination with other anti-cancer agents in patients with advanced metastatic colorectal cancer.
Conditions
- Metastatic Colorectal Cancer (CRC)
Interventions
HS-20093Drug
administered as an IV infusion
BevacizumabDrug
administered as an IV infusion
5-FUDrug
administered as an IV infusion
LeucovorinDrug
administered as an IV infusion
CapecitabineDrug
administered orally
OxaliplatinDrug
administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) for combination-treatmentsTime frame: Up to day 21 (arm 1/3/4) or 28 (arm 2/5) from the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.